A new gel treatment for debilitating knee pain, known as Arthrosamid, could offer significant cost savings to the UK's National Health Service (NHS) by reducing the need for knee replacement surgeries, according to columnist Richard Littlejohn.
Littlejohn, who recently underwent the procedure himself, described it as a simple, minimally invasive treatment involving six small injections into the affected knee under local anesthetic. He reported being pain-free within hours of the 15-minute procedure and regaining full mobility overnight. The treatment, developed in Copenhagen and originally used for horses, has been adapted for human use and is available in Canada and across Europe, where approximately 15,000 patients have received it.
Currently, Arthrosamid is only available privately in the UK, costing around £2,700. Littlejohn argues that if the NHS were to adopt the treatment, the bulk purchasing cost would likely be around £2,000 per treatment. He estimates that if Arthrosamid were deemed suitable for 80% of knee replacement cases, it could save the health service an estimated £70 million annually.
Knee replacement surgeries in the UK currently cost the NHS between £8,500 and £17,000 per operation, with waiting lists in some areas extending to a year. Littlejohn points out that Arthrosamid also spares patients the trauma of a lengthy knee replacement surgery, which can involve up to a six-hour procedure from pre-op to recovery room discharge, potential overnight hospital stays, and months of post-operative care, including painkillers and physiotherapy.
He further suggests that a single doctor could potentially treat up to two dozen patients a day with Arthrosamid, significantly reducing current waiting lists. Research from Denmark indicates that patients receiving a single treatment of Arthrosamid have experienced benefits lasting for at least four years.
Littlejohn's personal experience with the treatment followed six years of managing a debilitating knee condition with exercise and steroid injections, which had become increasingly ineffective. His consultant, hip and knee specialist Tim Waters, administered the Arthrosamid injections at Spire Elstree.
While the article focuses on the potential benefits of Arthrosamid for the NHS, it also touches on unrelated topics, including commentary on political figures and wildlife management.